[PRNewswire] Onconic Therapeutics Receives MFDS Approval for JAQBO
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SEOUL, South Korea April 25, 2024 /PRNewswire=연합뉴스/ -- Onconic Therapeutics, a leading biotechnology company in Korea, today announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the treatment of erosive gastroesophageal reflux disease (GERD) in adults.
JAQBO is a next-generation potassium competitive blocker (P-CAB) expected to become the new standard treatment in the market for gastric acid related diseases. JAQBO directly binds to proton pumps in a competitive manner to reduce gastric acid secretion. This novel mechanism allows quick onset of action regardless of the acidity level in the stomach, offering immediate symptom relief. In addition, longer duration of acid suppression with no food effect could provide a new paradigm in GERD treatment.
The MFDS approval of JAQBO is based on comprehensive results including the Phase III clinical trial across 28 sites in Korea. The study demonstrated JAQBO's effectiveness on erosive esophagitis, with a healing rate of 97.9% after 8 weeks of treatment. These results were presented at the United European Gastroenterology Week in October 2023.
Onconic Therapeutics aims to launch JAQBO this year after listing for National Healthcare Insurance Reimbursement in Korea. Domestic sales of JAQBO will be handled by Jeil Pharmaceutical, Onconic Therapeutics's parent company.
In March 2023, JAQBO was licensed out to Livzon Pharmaceutical Group, the leading seller of PPIs in China for development and commercialization, in a deal value of $127.5 million for Greater China.
Onconic Therapeutics is committed to enhancing gastrointestinal treatment and improving patient outcomes by expanding additional indications.
About Onconic Therapeutics
Onconic Therapeutics[http://onconic.co.kr/ ] is a Korean leader in developing novel drugs. With a focus on innovative research and clinical excellence, Onconic Therapeutics is dedicated to improving patient outcomes and providing quality healthcare solutions for cancer and gastrointestinal disorders.
Forward-Looking Statement
This press release contains forward-looking statements that are based on our current expectations, forecasts, and assumptions. These statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. Forward-looking statements include statements about our future financial performance, business strategy, plans and objectives. Factors that could cause such differences include but are not limited to economic conditions, market demand, competitive pressures, and regulatory changes. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release.
Source: Onconic Therapeutics
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 북, 한중일 정상회의 직후 정찰위성 발사했지만 실패(종합2보) | 연합뉴스
- 대통령실, 北 군사정찰위성 발사에 안보상황점검회의 개최 | 연합뉴스
- '한일중 회의체' 정례화 복원…"한반도 문제 정치적 해결 노력"(종합) | 연합뉴스
- "트럼프, 재집권시 주한미군 철수 걸고 김정은과 협상 가능성" | 연합뉴스
- 마지막까지 진통 연금 '구조개혁'은…숫자조정 아닌 '틀' 바꾸기 | 연합뉴스
- "특정장소 모아놓고 집단휴학계 제출 강요"…의대생들 수사의뢰 | 연합뉴스
- 사망 훈련병에 '완전군장 구보·푸시업' 지시…규정 위반 정황(종합2보) | 연합뉴스
- 외교부 조직개편 단행…한반도본부→외교전략정보본부로 확대 | 연합뉴스
- 尹 "한일중 교역·투자 활성화…기업 투자는 3국관계 안전판"(종합) | 연합뉴스
- 與 '채상병 특검법' 5명 공개 찬성…추가 이탈표 차단 부심(종합) | 연합뉴스